Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

TAIWAN: HCV Treatment Linked to Improved Outcomes in Diabetic Patients




 

Healio (12.12.2013) Aids Weekly Plus

Healio reported on a study of diabetic patients with hepatitis C virus (HCV) infection who received treatment with pegylated interferon plus ribavirin therapy. The researchers conducted a population-based cohort study to determine whether antiviral therapy for HCV infection resulted in improved outcomes in diabetic patients. The researchers reviewed records of 2,267,270 Taiwanese individuals with diabetes from a population-based cohort study and selected 1,411 patients who had received standard HCV treatment; 1,411 matched patients who had not received treatment; and 5,644 individuals who did not have HCV infection. The researchers recorded incidence of end-stage renal disease (ESRD), ischemic stroke, and acute coronary syndrome (ACS) among the three groups from 2003 to 2011. ESRD incidence among the treated patients was 1.1 percent, ischemic stroke 3.1 percent, and ACS 4.1 percent. Incidence in the untreated group was 9.3 percent, 5.3 percent, and 6.6 percent, respectively; while among the uninfected individuals incidence was 3.3 percent, 6.1 percent, and 7.4 percent, respectively. Multivariate adjusted hazard ratios were much lower for the group treated with antiviral therapy than for the untreated. The researchers concluded that risks of ESRD, ischemic stroke, and ACS were reduced in HCV patients who were treated with antiviral therapy compared to controls and that HCV may have a role in patients developing clinical complications of diabetes. They acknowledge that additional research is necessary to determine the role of HCV and its mechanisms in causing diabetic complications. The full report, “Antiviral Treatment for Hepatitis C Virus Infection is Associated with Improved Renal and Cardiovascular Outcomes in Diabetic Patients,” was published online in the journal Hepatology (2013; doi: 10.1002/hep.26892).



 


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.



Information in this article was accurate in December 17, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.